Members of the coronaviridae family are endemic to human populations and have caused
several epidemics and pandemics in recent history. In this review, we will discuss the …

Archaea are microorganisms more closely related to eukaryotes than bacteria. Almost 50
years after being defined as a new domain of life on earth, new species continue to be …

Nanobodies offer several potential advantages over mAbs for the control of SARS-CoV-2.
Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern …

Using our strongly immunogenic SmT1 SARS-CoV-2 spike antigen platform, we developed
antigens based on the Beta & Delta variants of concern (VOC). These antigens elicited …

Protein expression from stably transfected Chinese hamster ovary (CHO) clones is an
established but time‐consuming method for manufacturing therapeutic recombinant …

Background As the COVID-19 pandemic continues to evolve, novel vaccines need to be
developed that are readily manufacturable and provide clinical efficacy against emerging …

With the persistence of the SARS-CoV-2 pandemic and the emergence of novel variants, the
development of novel vaccine formulations with enhanced immunogenicity profiles could …

The SARS coronavirus 2 (SARS-CoV-2) spike (S) protein binding to the human ACE2
receptor is the molecular event that initiates viral entry into host cells and leads to infection …

Liposomes composed of sulfated lactosyl archaeol (SLA) have been shown to be a safe and
effective vaccine adjuvant with a multitude of antigens in preclinical studies. In particular …

The virus-like particle (VLP) platform is a robust inducer of humoral and cellular immune
responses; hence, it has been used in vaccine development for several infectious diseases …